Astria Therapeutics, Inc.
Clinical trials sponsored by Astria Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers compare two methods of delivering navenibart Results expected Sep 2026 (estimated)
- New shot could stop dangerous swelling attacks in HAE Results expected Dec 2026 (estimated)
-
New hope for HAE: Long-Term trial of navenibart launches
Disease control By invitation onlyThis Phase 3 trial tests the long-term safety and effectiveness of navenibart, an injectable drug, in 145 adults and teens with hereditary angioedema (HAE) who were in a previous study. The trial has two parts: first, everyone gets a fixed dose; then, some may switch to a persona…
Phase 3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New shot could stop dangerous swelling attacks in HAE
Disease control OngoingThis Phase 3 trial tests whether navenibart, a drug given as a shot under the skin, can prevent attacks in people with hereditary angioedema (HAE). About 145 adults and teens with HAE type 1 or 2 will receive either navenibart or a placebo for 6 months. The main goal is to see if…
Phase 3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug STAR-0310 put to the test in healthy people
Knowledge-focused OngoingThis early-stage study tests a new drug called STAR-0310 in 40 healthy adults to see if it is safe and how the body processes it. Participants receive either the drug or a placebo, and researchers monitor for side effects. This study does not aim to treat any disease; it is a fir…
Phase 1 • Sponsor: Astria Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC